ing, urticaria, and angioedema. Allergy Asthma Proc. 2015;36(3):230-233. doi:10.2500/aap.2015.36.3836.39. Van den Poel B, Kochuyt A-M, Del Biondo E, et al. Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients. Acta Clin Belg. 2017;72(2):123-129. doi:10.1080/17843286.2017.1293312.40. Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr-2017-221405. doi:10.1136/bcr-2017-221405.41. Álvarez-Twose I, González de Olano D, Sánchez-Muñoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125(6). doi:10.1016/j.jaci.2010.02.019.42. Seidel H, Molderings GJ, Oldenburg J, et al. Bleeding diathesis in patients with mast cell activation disease. Thromb Haemost. 2011;106(5):987-989. doi:10.1160/TH11-05-0351.43. Luzgina NG, Potapova O V, Shkurupiy VA. Structural and functional peculiarities of mast cells in undifferentiated connective tissue dysplasia. Bull Exp Biol Med. 2011;150(6):676-678. http://www.ncbi.nlm.nih.gov/pubmed/22235414. Accessed December 24, 2017.44. Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564-1569. doi:10.1038/ng.3696.45. Lyons JJ, Sun G, Stone KD, et al. Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol. 2014;133(5):1471-1474. doi:10.1016/j.jaci.2013.11.039.46. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol. 1999;29(8): 2645-2649.doi:10.1002/(SICI)1521-4141(199908)29:08 3.0.CO;2-1.47. Kimata M, Ishizaki M, Tanaka H, Nagai H, Inagaki N. Production of matrix metalloproteinases in human cultured mast cells: involvement of protein kinase C-mitogen activated protein kinase kinase-extracellular signal-regulated kinase pathway. Allergol Int. 2006;55(1):67-76. doi:10.2332/allergolint.55.67.48. Matsumoto KI, Minamitani T, Orba Y, Sato M, Sawa H, Ariga H. Induction of matrix metalloproteinase-2 by tenascin-X deficiency is mediated through the c-Jun N-terminal kinase and protein tyrosine kinase phosphorylation pathway. Exp Cell Res. 2004;297(2):404-414. doi:10.1016/j.yexcr.2004.03.041.49. Zweers MC, Hakim AJ, Grahame R, Schalkwijk J. Joint hypermobility syndromes: The pathophysiologic role of tenascin-X gene defects. Arthritis Rheum. 2004;50(9):2742-2749. doi:10.1002/art.20488.50. Vergnolle N, Bunnett NW, Sharkey KA, et al. Proteinase-activated receptor- 2 and hyperalgesia: A novel pain pathway. Nat Med. 2001;7(7):821-826. doi:10.1038/89945.51. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol. 1999;127(5):1083-1090. doi:10.1038/ sj.bjp.0702634.52. Schmidlin F, Amadesi S, Dabbagh K, et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol. 2002;169(9):5315-5321. http://www.ncbi.nlm.nih. gov/pubmed/12391252. Accessed February 20, 2018.53. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med. 2005;11(6):661-665. doi:10.1038/nm1245.54. Sevigny LM, Zhang P, Bohm A, et al. Interdicting protease-activated receptor- 2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci. 2011;108(20):8491-8496. doi:10.1073/pnas.1017091108.55. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303-313. doi:10.1016/j. cell.2004.12.018.56. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009;137(2):332-343. doi:10.1016/j.cell.2009.02.018.57. Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272(7):4043- 4049. http://www.ncbi.nlm.nih.gov/pubmed/9020112. Accessed February20, 2018.58. Noorbakhsh F, Tsutsui S, Vergnolle N, et al. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med. 2006;203(2):425-435. doi:10.1084/ jem.20052148.59. Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol.2002;161(5):1903-1915. doi:10.1016/S0002-9440(10)64466-5.60. Afrin L. Presentation, diagnosis, and management of mast cell activation syndrome. In: Mast Cells. ; 2013:Chapter 6. doi:10.1146/annurev.immunol. 21.120601.141110.61. Fukuyama T, Martel BC, Linder KE, Ehling S, Ganchingco JR, Bäumer W. Hypochlorous acid is antipruritic and anti-inflammatory in a mouse model of atopic dermatitis. Clin Exp Allergy. 2018;48(1):78-88. doi:10.1111/cea.13045.62. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous Acid Generated by Myeloperoxidase Modifies Adjacent Tryptophan and Glycine Residues in the Catalytic Domain of Matrix Metalloproteinase-7 (Matrilysin). J Biol Chem. 2003;278(31):28403-28409. doi:10.1074/jbc.M304739200.63. Stechmiller J, Cowan L, Schultz G. The Role of Doxycycline as a Matrix Metalloproteinase Inhibitor for the Treatment of Chronic Wounds. Biol Res Nurs. 2010;11(4):336-344. doi:10.1177/1099800409346333.64. Tae H-J, Marshall S, Zhang J, Wang M, Briest W, Talan MI. Chronic Treatment with a Broad-Spectrum Metalloproteinase Inhibitor, Doxycycline, Prevents the Development of Spontaneous Aortic Lesions in a Mouse Model of Vascular Ehlers-Danlos Syndrome. J Pharmacol Exp Ther. 2012;343(1):246-251. doi:10.1124/jpet.112.197020.65. Ahmad N, Mukhtar H. Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004;123(3):417-425. doi:10.1111/j.0022- 202X.2004.23307.x.66. Ogawa K, Shichishima A, Ikeda K, et al. [Systemic mastocytosis with coagulation abnormalities and gastrointestinal symptoms]. Nihon Naika Gakkai Zasshi. 2009;98(1):141-143. http://www.ncbi.nlm.nih.gov/ pubmed/19227918. Accessed January 6, 2018.67. Afrin LB. Burning mouth syndrome and mast cell activation disorder. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology. 2011;111(4):465- 472. doi:10.1016/j.tripleo.2010.11.030.68. Afrin LB. Mast cell activation syndrome masquerading as agranulocytosis. Mil Med. 2012;177(1):113-117. http://www.ncbi.nlm.nih.gov/pubmed/22338992. Accessed December 24, 2017.69. Asawa A, Simpson KH, Bonds RS. Ketotifen use in a patient with fire ant hypersensitivity and mast cell activation syndrome. Ann Allergy Asthma Immunol. 2015;114(6):443-446. doi:10.1016/j.anai.2015.03.009.70. Richter EW, Hsu K-L, Moll V. Successful Management of a Patient With Possible Mast Cell Activation Syndrome Undergoing Pulmonary Embolectomy:A Case Report. A A
AUTHOR CORRESPONDENCE
Adam J. Friedman MD ajfriedman@mfa.gwu.edu